Moss, 13 March 2024

Gentian Diagnostics (Gentian), a leading manufacturer of cystatin C, is proud to
announce its commitment to kidney care following the release of the KDIGO 2024
Clinical Practice Guideline for Chronic Kidney Disease (CKD). The guideline
underscores the pivotal role of cystatin C in estimating glomerular filtration
rate (GFR) and tailoring treatment decisions based on individual kidney function
status, especially when combined with creatinine. The latest guidelines which
recommends increased use of cystatin C aims to improve patient care,
particularly in scenarios where precise dosing of medications is paramount.
 
Cystatin C-based assessments offer a more reliable estimation of GFR, enabling
healthcare providers to make informed decisions tailored to each patient's
unique kidney function profile. By leveraging the accuracy of cystatin C
alongside creatinine, clinicians can optimize treatment strategies, ensuring
that medication dosages are precisely calibrated to individual kidney function
status. This advancement is crucial for enhancing patient outcomes and
minimizing risks associated with improper dosing.
 
Gentian's dedication to offering high-quality cystatin C aligns well with the
standards outlined in the KDIGO 2024 CKD guidelines. The company's focus on
precision and reliability in GFR assessments reflects a commitment to excellence
in kidney care, empowering healthcare professionals with the tools needed to
deliver personalized treatment plans that prioritize patient well-being.
 
As Gentian continues to drive innovation in precision medicine through its
diagnostics assay portfolio, the company remains at the forefront of
transforming kidney care and improving patient outcomes. By adhering to the
latest guidelines and leveraging state-of-the-art solutions, Gentian reaffirms
its mission to revolutionize healthcare through advanced diagnostics and
personalized treatment approaches.
 
For more information about Gentian Diagnostics and its innovative cystatin C
solutions, please visit www.gentian.com

For sales and marketing enquiries
Markus Jaquemar, CCO markus.jaquemar@gentian.com   +47 919 21 709 
 
For investor enquiries
Njaal Kind, CFO 
Njaal.kind@gentian.com   +47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.